Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company whose news flow centers on its Light Adjustable Lens system and corporate developments related to cataract surgery care. Company press releases describe RxSight as dedicated to providing high-quality customized vision to patients following cataract surgery through its Light Adjustable Lens (LAL/LAL+) and Light Delivery Device (LDD) platform.
News updates for RXST commonly include financial and operating results, such as quarterly revenue, procedure volumes for Light Adjustable Lenses, and the number of Light Delivery Devices sold and installed. These releases often discuss trends in LAL procedure volumes, changes in the installed base of LDDs, and guidance ranges for revenue and gross margin. Investors and observers can use these announcements to track how adoption of the Light Adjustable Lens system is progressing across cataract practices.
RxSight’s news also highlights corporate and leadership developments, including transitions in the Chief Financial Officer role and appointments to the Board of Directors and Board committees, as disclosed in press releases and related Form 8-K filings. In addition, the company regularly announces participation in major healthcare and ophthalmology conferences, where management presents to investors and engages with surgeons and other stakeholders.
Another recurring theme in RxSight’s news is commercial and clinical engagement activity. The company has reported initiatives such as practice development programs and Live Learning Sessions at ophthalmology meetings, where surgeons share real-world experience with the Light Adjustable Lens and discuss clinical and practice-level impacts.
This RXST news page aggregates these types of updates in one place, allowing readers to follow RxSight’s reported financial performance, leadership changes, conference participation, and initiatives related to its Light Adjustable Lens technology over time.
RxSight (Nasdaq: RXST) reported preliminary unaudited results for Q4 and full-year 2025 and named a new CFO effective Jan 11, 2026. Preliminary Q4 2025 revenue is expected to be approximately $32.6M, driven by sales of 28,611 Light Adjustable Lenses (LAL, +10% vs Q3 2025) and 25 Light Delivery Devices (LDD), bringing the installed base to 1,134 LDDs as of Dec 31, 2025. Preliminary FY2025 revenue is expected to be approximately $134.5M (vs prior guidance $125–$130M), with total LAL sales of 109,615 (+12% vs 2024) and 163 LDDs sold in 2025. Cash and short-term investments are expected to be $228.1M. Audited 2025 results and 2026 guidance will be released with Q4 earnings in February. Mark Wilterding is appointed CFO effective Jan 11, 2026.
RxSight (NASDAQ:RXST) announced that its management will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 3:45 p.m. PT / 6:45 p.m. ET.
Investors and interested parties can access a live and archived webcast of the presentation at https://investors.rxsight.com/. No financial results or guidance were included in the announcement.
RxSight (NASDAQ:RXST) announced that Shelley Thunen, its Chief Financial Officer, is transitioning from the CFO role and will remain with the company until the sooner of her successor's appointment or January 31, 2026. Ms. Thunen has agreed to support RxSight as a consultant after the transition.
The release highlights Ms. Thunen's nearly decade of service, her role in the company's 2021 IPO, and operational achievements under her finance leadership, including more than 1,100 light-adjustable intraocular devices (LDDs) in the field and over 250,000 procedures performed. The CEO and board expressed gratitude for her contributions.
RxSight (NASDAQ: RXST) will present at the Piper Sandler 37th Annual Healthcare Conference in New York City.
Management is scheduled to present on Wednesday, December 3, 2025 at 12:00 p.m. ET. A live and archived webcast will be available at the company's investor site.
RxSight (Nasdaq: RXST) reported third quarter 2025 results: Q3 revenue $30.3M (down 14% YoY) driven by 26,045 LAL lenses sold (+6% procedure volume) and 25 LDD devices sold (-69%). Gross margin was 80% (+844 bps YoY). The company narrowed full‑year 2025 revenue guidance to $125.0M–$130.0M, raised full‑year gross margin guidance to 76%–77%, and kept operating expense guidance at $145M–$155M (including stock‑based comp of $30M–$32M). Cash and short‑term investments totaled $227.5M as of September 30, 2025.
RxSight (Nasdaq: RXST) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025.
Management will discuss results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. To join by phone dial (800) 715-9871 or (646) 307-1963 and enter conference code 6619966.
The call will be broadcast in listen-only mode and archived on the company investor relations site at https://investors.rxsight.com/.
RxSight (Nasdaq: RXST) will host multiple Live Learning Sessions at AAO 2025 in Orlando, Oct 18–20, at Booth #2931. Sessions feature surgeons sharing real-world experience with the Light Adjustable Lens, focusing on clinical advantages and economic implications of adjustability.
Scheduled talks run Oct 18 (10:00 AM–3:00 PM) and Oct 19 (10:00 AM–1:00 PM) and cover topics such as ROI, career impact, premium lens adoption, patient-centered outcomes, and practical counseling for Light Adjustable Lens patients.
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has announced its participation in the upcoming Morgan Stanley Healthcare Conference in New York City.
The company's management team will deliver their presentation on September 8, 2025, at 10:45 AM ET. Investors can access both the live presentation and archived webcast through the company's investor relations website at investors.rxsight.com.
Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.
Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Wells Fargo Healthcare Conference in Boston. The company's management will deliver their presentation on September 4, 2025, at 10:15 AM ET. Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.rxsight.com.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
